Compare ALLT & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLT | PRTC |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.1M | 386.7M |
| IPO Year | 2006 | N/A |
| Metric | ALLT | PRTC |
|---|---|---|
| Price | $9.86 | $16.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.75 | N/A |
| AVG Volume (30 Days) | ★ 455.0K | 4.8K |
| Earning Date | 11-20-2025 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.02 | ★ 0.20 |
| Revenue | ★ $98,512,000.00 | $6,391,000.00 |
| Revenue This Year | $12.44 | N/A |
| Revenue Next Year | $12.98 | N/A |
| P/E Ratio | $457.61 | ★ $7.77 |
| Revenue Growth | 7.51 | ★ 1265.60 |
| 52 Week Low | $4.37 | $13.30 |
| 52 Week High | $11.42 | $23.35 |
| Indicator | ALLT | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 51.09 |
| Support Level | $9.68 | $16.44 |
| Resistance Level | $10.35 | $17.17 |
| Average True Range (ATR) | 0.39 | 0.35 |
| MACD | 0.10 | 0.12 |
| Stochastic Oscillator | 62.50 | 55.29 |
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.